MLN1202 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002567-24-GB
(EUCTR)
09/10/200622/02/2005A Phase 2a Magnetic Resonance Study of the Safety and Efficacy of MLN1202 in Patients with Multiple Sclerosis - Not applicableA Phase 2a Magnetic Resonance Study of the Safety and Efficacy of MLN1202 in Patients with Multiple Sclerosis - Not applicable The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).
MedDRA version: 8.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Product Name: MLN1202
Product Code: MLN1202
Millennium Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
160Phase 2Hungary;Czech Republic;United Kingdom
2EUCTR2004-002567-24-HU
(EUCTR)
19/07/200506/04/2005A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not applicableA Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not applicable The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).Product Name: MLN1202
Product Code: MLN1202
INN or Proposed INN: Not yet available
Other descriptive name: Not yet available
Millennium Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
160Phase 2Hungary;United Kingdom;Czech Republic
3NCT01199640
(ClinicalTrials.gov)
May 20059/9/2010Study of the Safety and Efficacy of MLN1202 in Patients in Multiple SclerosisA Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple SclerosisMultiple SclerosisDrug: MLN1202Millennium Pharmaceuticals, Inc.NULLCompleted18 YearsN/ABoth50Phase 2NULL
4EUCTR2004-002567-24-CZ
(EUCTR)
04/04/200504/02/2005A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcableA Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).Product Name: MLN1202
Product Code: MLN1202
INN or Proposed INN: Not yet available
Other descriptive name: Not yet available
Millennium Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
160Phase 2Hungary;United Kingdom;Czech Republic